KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aproximadaProbabilidad implícita actualBefore Jan 1, 2031 56%Líder entre 6 opciones
Calidad del mercado
37 / 100
Baja calidadVolumen 24h
0 €
Liquidez
1,3 mil €
Baja liquidezCompra / Venta
10.0% / 16.0%
Spread
6.0 pt
Spread amplioDatos de mercado
Actualizado hace 23 minutos
14 may 26, 2:001 ene 27, 4:59
Tendencias
Solo fondos simulados, sin dinero realNo es asesoramiento financiero
Resultado elegido
Before Jan 1, 202710%
Tendencia de volumen
$22 jul10d de datos27 jul
Mercados Relacionados
Will the FDA approve camizestrant for advanced breast cancer?
47 €Before Oct 1, 2026: 37%KALSHI
KALSHI
Hantavirus pandemic in 2026?
92,7 mil €Sí: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
7,5 mil €26-27M: 88%POLYMARKET
POLYMARKET
New pandemic in 2026?
5,1 mil €Sí: 9%POLYMARKET
POLYMARKET
Measles cases in 2026?
2,4 mil €Above 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
2,1 mil €Sí: 5%KALSHI
KALSHIActivos en estos temas
Reglas
If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: